![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 37, 33537-33540, September 13, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,
¶
From the
Program in Cell, Molecular, and
Developmental Biology, Sackler School of Biomedical Sciences, Tufts
University, Boston, Massachusetts 02111, § Center for
Cardiovascular Sciences, Albany Medical College, Albany, New York
12208, and ¶ Department of Anatomy and Cell Biology, Tufts
University School of Medicine, Boston, Massachusetts 02111
Received for publication, June 4, 2002, and in revised form, July 18, 2002
| |
ABSTRACT |
|---|
|
|
|---|
The CaMK II1 is found in
virtually all tissues examined and is thought to play a role in diverse
cellular processes such as neurotransmitter release (1, 2), vascular
smooth muscle cell (VSMC) migration (3), contraction (4), and
transcription of genes (5, 6). Recent evidence also suggests that CaMK
II regulates the induction of VSMC contraction by regulating the
phosphorylation of myosin light chain kinase. Caldesmon and
calponin, two other proteins involved in contraction, are also
postulated to be substrates for CaMK II. Both these proteins can
inhibit actin-activated myosin ATPase; however, when phosphorylated by
CaMK II they lose their ability to inhibit actomyosin ATPase (7).
Despite the potentially important role of CaMK II in VSMC contraction,
there is minimal information available about its regulation in
vivo. Furthermore, the relative abundance of this enzyme implies a
role in other cellular functions, but the lack of other physiologically relevant substrates (besides calponin and caldesmon) for CaMK II in
VSMCs has blunted the analysis of other putative functions. Here we
report that the S18 protein of the 40 S ribosome is a potential
substrate of CaMK II. While almost nothing is known about the function
of S18 in animal cells, it is a highly basic protein showing high
homology to the Escherichia coli ribosomal protein rpS13.
rpS13 plays important roles in both initiation and elongation during
protein translation and is thought to help regulate translational
efficiency. Hence, the identification of S18 as a putative substrate
for CaMK II may provide a novel link between
Ca2+-mobilizing agents and protein translation control.
Materials--
All tissue culture plasticware was obtained from
Costar (Cambridge, MA) and Falcon (BD PharMingen). Fetal calf serum was
purchased from Hyclone (Logan, UT). RPMI base medium,
trypsin-EDTA, glutamine, and penicillin-streptomycin were purchased
from Invitrogen. Heparin, obtained from Glycomed (Alameda, CA), was
derived from porcine mucosa (sodium salt) (molecular mass, 12-18 kDa).
Chondroitin sulfate and reagents for buffers, cell extraction, and
SDS-gel electrophoresis were from Sigma. Platelet-derived growth
factor was from R&D Systems (Minneapolis, MN), and
lysophosphatidic acid was from Sigma. Acrylamide solution (Protogel)
was from National Diagnostics (Atlanta, GA). Horseradish
peroxidase-conjugated goat anti-mouse IgG was from Invitrogen;
horseradish peroxidase-conjugated sheep anti-rabbit IgG was obtained
from Roche Molecular Biochemicals. Sodium orthovanadate was from Sigma;
okadaic acid, calyculin, tautomycin, and KN-93 were from Calbiochem.
[3H]Leucine was from PerkinElmer Life Sciences.
Cell Culture--
Rat aortic smooth muscle cells from
Sprague-Dawley rats (Charles River Breeding Laboratories, Inc.) were
isolated, cultured, and characterized as described previously (8).
Briefly, the abdominal segment of the aorta was removed, and the fascia
was cleaned away under a dissecting microscope. The aorta was cut longitudinally, and small pieces of the media were carefully stripped from the vessel wall. Two or three such strips were placed in 60-mm
dishes. Within 1-2 weeks, VSMCs migrated from the explants; they were
capable of being passaged approximately 1 week after the first
appearance of cells. They were identified as smooth muscle cells by
their "hill and valley" growth pattern and indirect immunofluorescence staining for VSMC-specific Growth Arrest of Cells--
Cells were routinely plated at
5-6 × 105/100-cm2 dish, washed with
RPMI, and placed in RPMI containing 0.2-0.4% FCS for 72 h (10).
Flow microfluorometry and determination of
[3H]thymidine-labeled nuclei indicated that greater than
95% of the cells were arrested in G0(G1).
Cells were released from quiescence by replacing the low serum medium
with normal growth medium (i.e. RPMI 1640 containing 10%
FCS). The cells were ~40-60% confluent at the time of harvest.
Protein Analysis--
Quiescent cells were treated with 10%
FCS, RPMI with or without the indicated concentrations of heparin or
chondroitin sulfate for various time intervals. The proteins were then
harvested as follows with all procedures performed at 4 °C. Cells
were rinsed twice with cold TBS (20 mM Tris, pH 8, 137 mM NaCl) and lysed with 100 µl of lysis buffer (TBS + 1% Nonidet P-40, 10% glycerol, 100 mM sodium fluoride, 2 mM phenylmethylsulfonyl fluoride, 20 µg/ml aprotinin, 1 µg/ml leupeptin, 0.5 mM sodium orthovanadate). The
extracts were rocked for 20 min and centrifuged at 12,000 rpm
(Eppendorf microcentrifuge) for 10 min to remove insoluble material.
The supernatant was stored at Protein Synthesis Measurements--
Protein synthesis was
measured as described previously for smooth muscle cells (12). Briefly,
2 × 104 VSMCs were plated into 24-well microplates. 2 days later, 2 µCi/ml [3H]leucine was added to the
culture medium in the presence or absence of 30 µM KN-93,
a specific inhibitor of CaMK II (1). After 2 h, cells were washed
five times with ice-cold phosphate-buffered saline, and 1.0 ml of
ice-cold 10% trichloroacetic acid (w/v) was added to each well.
The cells were incubated on ice for 1 h and washed five times with
ice-cold 10% trichloroacetic acid. 1.0 ml of 1.0 M NaOH
was added to each well overnight at 37 °C, pH was neutralized
with 10 M HCL, and a small portion was counted using liquid
scintillation spectroscopy. Replicate wells within the same multiwell
plate were harvested for both protein determination and cell
counting (12). To ensure that intracellular and extracellular leucine
pools were completely equilibrated and that the specific radioactivity
of leucyl-tRNA was unchanged by KN-93, the methods outlined by Gulves
and Dice were followed (13). Under the conditions used in our
experiments, these parameters were found not to contribute to the
changes in protein synthesis rates observed in the presence of
KN-93.
Radioactive Labeling and Immunoprecipitation of CaMK
II--
Quiescent cells were rinsed in phosphate-free RPMI and
incubated in this medium for 2 h in the presence of 200 µCi/ml
[ Immunoprecipitation and Purification of p20--
Quiescent VSMCs
were stimulated with 10% FCS, RPMI, and the cell lysates were used for
immunoprecipitation with the anti-CaMK II CaMK II Inhibitor KN-93--
Quiescent VSMCs were radioactively
labeled with [ A 20-kDa Protein Co-immunoprecipitates with CaMK II--
We have
reported that heparin inhibits CaMK II phosphorylation and activation
(15, 34). In these experiments, growth-arrested VSMCs were
radioactively labeled with [ p20 Is the S18 Protein of the 40 S Ribosome--
Based on the
observations that 1) the phosphorylation of both CaMK II and p20 was
inhibited by heparin and 2) p20 co-immunoprecipitated with CaMK II, we
considered the possibility that p20 might be a novel substrate of CaMK
II. To identify this protein, we performed a large scale
immunoprecipitation with anti-CaMK II antibodies on serum-treated VSMC
lysates. The immunoprecipitates were resolved by SDS-PAGE and stained
with Colloidal Coomassie Blue stain. The p20 protein band was excised
from the gel and submitted for sequence analysis. Two peptides were
sequenced, and both peptides exhibited 100% homology to the
corresponding sequence of the rat ribosomal protein S18 of the 40 S
ribosome (Fig. 2).
S18 Is Phosphorylated by CaMK II--
To test whether cellular S18
was phosphorylated by CaMK II, we used KN-93, a specific inhibitor of
CaMK II (1). Quiescent VSMCs were radioactively labeled for 2 h
with [ Protein Synthesis Rates Are Reduced When CaMK II Activity and S18
Phosphorylation Are Inhibited--
If S18 phosphorylation by CaMK II
plays a role in regulating translational efficiency, then inhibiting
S18 phosphorylation with KN-93 should reduce protein synthesis rates in
VSMCs. To test this hypothesis, we added [3H]leucine to
exponentially growing VSMCs in the presence or absence of 30 µM KN-93 (Table I), a
concentration that reduces S18 phosphorylation by ~74% (Fig. 3).
Using two independently isolated VMSC cultures, KN-93 reduced protein
synthesis rates by an average of 24%. Control experiments (12, 13)
indicate that the intracellular leucine pool is fully equilibrated,
that the leucyl-tRNA fraction is unchanged in the presence of KN-93,
and that >95% of the cell protein is collected by the methods used
(data not shown).
This study provides evidence that the S18 protein of the 40 S
ribosome can be phosphorylated by CaMK II, thus identifying a putative
substrate for CaMK II in VSMCs. The evidence includes 1) a physical
association of S18 with CaMK II as determined by co-immunoprecipitation
of the two proteins and 2) pharmacologic suppression of S18
phosphorylation by two inhibitors of CaMK II, heparin and KN-93.
Furthermore, inhibiting phosphorylation of S18 with KN-93 also produced
a reduction in protein translation rates.
Although the initial observation of a putative CaMK II/S18 interaction
was made using heparin, work in our laboratory (10, 15, 34) and
by others (18-20) clearly indicates that heparin inhibits kinases
other than CaMK II. We therefore used the highly specific CaMK II
inhibitor KN-93 to confirm this interaction. KN-93 is a more
hydrophilic analogue of the isoquinolinyl sulfonamide KN-62. Both these
inhibitors prevent the activation of CaMK II by interacting with the
calmodulin binding domain of the kinase (1). KN-93 has no significant
effects on myosin light chain kinase, protein kinase C, or protein
kinase A at the concentrations used in the current study (17). KN-93
pretreatment resulted in an attenuation of CaMK II phosphorylation upon
FCS stimulation. A concomitant reduction in S18 phosphorylation as well
as the reproducible co-immunoprecipitation of S18 with CaMK II may
provide a link between calcium-mobilizing agents and protein
translation. This hypothesis is supported by the observation that the
inhibition of S18 phosphorylation is accompanied by a 24% reduction in
protein synthesis.
Little is known about the eukaryotic S18 protein except for its
sequence. However, its prokaryotic homolog, the E. coli
rpS13, has been studied more extensively, and the available data may provide insights into the role of S18 protein in eukaryotes, especially since there are many conserved domains between the two. Both S18 and
rpS13 are very basic proteins (21, 22). The E. coli rpS13 is
thought to be involved in the initiation of translation as it is a
surface protein at the interface of the ribosomal subunits that
cross-links to all three initiation factors (23). It interacts strongly
with the 20 S rRNA and has been cross-linked to the 3' major domain of
the 16 S rRNA (24-26), to ribosomal protein S19 (27), and to tRNA in
both the P and A sites (25, 28). These studies indicate that
rpS13 is important for both translation initiation and elongation.
rpS13 can be phosphorylated by a eukaryotic protein kinase (29), and
there are a number of phosphorylation sites in the eukaryotic S18
protein for phosphorylation by casein kinase II, protein kinase C, and
a tyrosine kinase.
Based on the high degree of homology between S18 and rpS13, it is
possible that S18 plays an important role in ribosome assembly as well
as in translational efficiency. In support of this idea, a mutant of
the E. coli rpS13 protein lacking the C-terminal 19 amino
acids shows a 20-30% reduction in translation rate (30) in agreement
with the 24% drop in protein synthesis rates observed when S18
phosphorylation is blocked in VSMCs. Interestingly the C-terminal
portion is required for 16 S rRNA recognition (31), and the consensus
motif for CaMK II phosphorylation is present within the C-terminal 19 residues of the protein sequence of S18.
The notion that phosphorylation of S18 regulates the rate of
translation becomes even more interesting in light of the ability of
heparin to inhibit both CaMK II and protein kinase C, both of which can
phosphorylate the S18 protein (22), implying that heparin may alter
translation rates. Although previous studies have indicated that
heparin blocks proliferation of VSMC, this glycosaminoglycan alters the
overall rate of protein synthesis in VSMCs by 20% or less (12). When
one considers that growth regulatory proteins are very labile and
comprise a very small percentage of the total protein in a cell while
housekeeping proteins are generally much more stable, even large
fluctuations in the levels of growth regulatory proteins would not be
detected when measuring overall protein synthesis. In addition,
mRNA encoding growth regulatory proteins has a very short
half-life; thus, even a modest reduction in translation rate such as
the 20-30% decrease seen in rpS13 mutants and the 23% reduction
observed with underphosphorylated S18 would result in the rapid
degradation/reduction of these nascent message levels in the cell.
The co-immunoprecipitation of a 20-kDa protein with CaMK II only in the
presence of mitogenic stimulation has been reported earlier (32).
However, further studies to identify the protein were not reported.
There is one prior observation of differential phosphorylation of a
ribosomal protein (33). However, this effect was independent of the
cytosolic free Ca2+ pool and thus was not a result of
calmodulin-dependent protein kinases; instead, it is a
reflection of the sequestered pool of intracellular Ca2+.
In contrast, serum treatment causes an increase in intracellular Ca2+ levels, a key factor in proliferative responses.
Exploring the connection between CaMK II and S18 should provide a
better understanding of the antiproliferative mechanism of heparin and
may shed new light on the relationship between
Ca2+-mobilizing agents and protein translation.
-isoform of
Ca2+/calmodulin-activated protein kinase II
(CaMK II) is abundantly expressed in vascular smooth muscle, but relatively little is known about its regulation or its potential cellular substrates. There are few, if any, known substrates of CaMK II
that are physiologically relevant in vascular smooth muscle cells.
Studies presented earlier (Mishra-Gorur, K., Singer, H. A.,
and Castellot, J. J., Jr. (2002) Am. J. Pathol., in press) by our laboratory show an inhibitory effect of heparin on CaMK II
phosphorylation and activity. During these studies we observed the
specific co-immunoprecipitation of a 20-kDa protein with CaMK II.
Purification and sequence analysis indicate that this protein is the
S18 protein of the 40 S ribosome. S18 was found to be abundantly phosphorylated in response to serum treatment, and this effect was
strongly inhibited by heparin. In addition, KN-93, a specific CaMK II
inhibitor, blocks S18 phosphorylation in vascular smooth muscle cells;
a concomitant 24% reduction in protein synthesis was observed. Taken
together these data support the idea that S18 could be a novel
substrate for CaMK II, thus providing a potential link between
Ca2+-mobilizing agents and protein translation.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-actin. VSMC cultures were maintained in RPMI 1640, 10% fetal calf serum at 37 °C
in a 5% CO2, 95% air incubator. Primary cultures were
used at or before passage 9. Cells were counted using a Coulter Counter
(Coulter Counter Corp., Hialeah, Fl). Cells were routinely grown in
RPMI 1640, 10% fetal calf serum (FCS). SV40 large T
antigen-transformed heparin-resistant and -sensitive cells (9) were
grown and maintained under similar conditions.
20 °C until use. Protein estimations
were done by the Pierce BCA method adapted for microtiter plates.
Extracts containing 50 µg of protein were boiled with 1× SDS sample
loading buffer, resolved by SDS-PAGE (11), and blotted onto
nitrocellulose membrane (Schleicher & Schüll) in Towbin
buffer (25 mM Trizma (Tris base), 192 mM
glycine, 20% methanol) at 250 mA overnight. The blots were stained
with Ponceau stain to confirm equal loading and transfer of proteins to
the membrane. The membranes were blocked with 5% milk in 1× TBS (20 mM Tris base, 137 mM NaCl, pH 7.6), and Western
blots were performed using anti-phosphotyrosine or anti-phosphoserine
antibodies (1:1000) and horseradish peroxidase-conjugated anti-mouse
IgG (1:10,000) in 1× TBST (TBS + 0.2% Tween 20). The proteins were
visualized using the DuPont Renaissance Enhanced ChemiLuminescence
detection reagents and autoradiography as described by the
manufacturer. Prestained protein standard markers (Invitrogen) were
used as molecular weight markers. Densitometric analysis on the
autoradiograms was performed using the Stratagene (La Jolla, CA) Eagle
Eye II system and the Scanalytics (Billerica, MA) ONE D-scan software.
-32P]ATP (14). Cells were then treated with 10% FCS,
RPMI + heparin or with 1 µM ionomycin, RPMI + heparin.
Proteins were harvested in Buffer A (50 mM MOPS, pH 7.4, 2 mM EGTA, 100 mM NaF, 100 mM sodium
pyrophosphate, 2 mM dithiothreitol, 0.2 mM
phenylmethylsulfonyl fluoride, 1% Nonidet P-40, and 0.4 unit/ml
aprotinin) and allowed to sit on ice for 5 min, and the lysates were
cleared by centrifugation at 10,000 rpm for 10 min at 4 °C. The
supernatant was used for immunoprecipitation with anti-CaMK II
antibodies (90 min at 4 °C) and protein A + G-agarose beads
(Oncogene Science) (60 min at 4 °C). The immunoprecipitates were
resolved by SDS-PAGE and blotted onto nitrocellulose, and differential
phosphorylation was analyzed after overnight exposure on a PhosphorImager.
-isoform-specific
antibodies as described above. The immunoprecipitates were resolved by
SDS-PAGE, and the proteins were visualized by Colloidal Coomassie Blue
staining. The p20 band was excised from the gel and submitted for
sequence analysis to the Harvard microsequencing facility.
-32P]ATP as described above. 90 min into the incubation, KN-93 was added to a final concentration of 30 µM. After 30 min the cells were stimulated with 10% FCS
for 5 min. The proteins were then harvested and used for
immunoprecipitation as described above.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-32P]ATP followed by
stimulation with 10% FCS, RPMI + heparin for 5 min. The cell lysates
were then used for immunoprecipitation with anti-CaMK II
-isoform-specific antibodies. This antibody was chosen because the
-isoform is the predominant form found in VSMCs (16), and the
antibody is highly specific as it is made against the NFSGGTSLWQNI
peptide unique to the C terminus of the
2-isoform (16, 17). A single
protein (Mr ~ 20,000; p20) was found to
co-immunoprecipitate with CaMK II (Fig.
1). In addition, p20 was abundantly
phosphorylated upon serum stimulation, and this effect was potently
inhibited by heparin. Control immunoprecipitations with the agarose
beads alone were performed to ensure that p20 was not simply
interacting with the beads.

View larger version (88K):
[in a new window]
Fig. 1.
A 20-kDa protein co-immunoprecipitates with
CaMK II. Radioactively labeled, quiescent VSMCs were treated with
10% FCS, RPMI + heparin for 5 min. The cell lysates were used for
immunoprecipitation with anti-CaMK II
-isoform-specific antibody.
The immunoprecipitates were resolved by SDS-PAGE and blotted onto
nitrocellulose, and phosphorylation was visualized by autoradiography.
Go, quiescent VSMCs; H, heparin; Iono,
ionomycin.

View larger version (16K):
[in a new window]
Fig. 2.
p20 exhibits a high degree of homology to the
rat S18 ribosomal protein of the 40 S ribosome. A large scale
immunoprecipitation was performed on VSMC lysates using anti-CaMK II
-isoform-specific antibody, and proteins were resolved by SDS-PAGE
as described above. The p20 protein band was excised from the gel and
submitted for sequence analysis. The sequence of the two peptides is
shown in bold letters.
-32P]ATP. 90 minutes into the incubation, KN-93
was added to the medium at a final concentration of 30 µM. After 30 min of incubation with KN-93 the cells were
treated with 10% FCS or 1 µM ionomycin for 5 min. Cells
were harvested, and the lysates were used for immunoprecipitation with
anti-CaMK II
-isoform-specific antibodies. Quiescent cells
and cells treated with KN-93 alone were used as controls.
Immunoprecipitation with beads alone was done to confirm the
specificity of the co-immunoprecipitation. KN-93 treatment resulted in
a reduction of CaMK II phosphorylation due to either FCS or ionomycin
stimulation (Fig. 3). A concomitant
reduction in the phosphorylation of the S18 protein was observed,
suggesting that S18 is phosphorylated by CaMK II (Fig. 3).

View larger version (64K):
[in a new window]
Fig. 3.
S18 is phosphorylated by CaMK II.
Radioactively labeled, quiescent VSMCs were treated with 30 µM KN-93 for 30 min followed by stimulation with 10%
FCS, RPMI + heparin or 1 µM ionomycin + heparin for 5 min. The cell lysates were used for immunoprecipitation with anti-CaMK
II
-isoform-specific antibody. The immunoprecipitates were resolved
by SDS-PAGE and blotted onto nitrocellulose, and phosphorylation was
visualized by autoradiography. KN93+FCS, cells
treated with both KN-93 and 10% FCS, RPMI; FCS, cells
treated with 10% FCS, RPMI alone; FCS(Beads
alone), control immunoprecipitation with beads alone on cells
treated with 10% FCS, RPMI; Iono, cells treated with 1 µM ionomycin alone; KN93+Iono,
cells treated with KN-93 followed by ionomycin. Densitometric analysis
(not shown) indicates that KN-93 reduces phosphorylation of S18 by 74%
in serum-treated cells.
S18 phosphorylation affects protein synthesis rates in VSMCs
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grants HL49973 (to J. J. C.) and HL49426 (to H. A. S.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom all correspondence should be addressed: Dept. of
Anatomy and Cell Biology, Tufts University School of Medicine, 136 Harrison Ave., Boston, MA 02111. Tel.: 617-636-0303; Fax:
617-636-0304.
Published, JBC Papers in Press, July 26, 2002, DOI 10.1074/jbc.C200342200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: CaMK II, Ca2+/calmodulin-activated protein kinase II; VSMC, vascular smooth muscle cell; FCS, fetal calf serum; MOPS, 4-morpholinepropanesulfonic acid.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Sumi, M., Kiuchi, K., Ishikawa, T., Ishii, A., Hagiwara, M., Nagatsu, T., and Hidaka, H. (1991) Biochem. Biophys. Res. Commun. 181, 968-975[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Benfenati, F., Valtorta, F., Rubenstein, J. L., Gorelick, F. S., Greengard, P., and Czernik, A. J. (1992) Nature 359, 417-420[CrossRef][Medline] [Order article via Infotrieve] |
| 3. |
Pauly, R. R.,
Bilato, C.,
Sollott, S. J.,
Monticone, R.,
Kelly, P. T.,
Lakatta, E. G.,
and Crow, M. T.
(1995)
Circulation
91,
1107-1115 |
| 4. |
Tansey, M. G.,
Word, R. A.,
Hidaka, H.,
Singer, H. A.,
Schworer, C. M.,
Kamm, K. E.,
and Stull, J. T.
(1992)
J. Biol. Chem.
267,
12511-12516 |
| 5. |
Wegner, M.,
Cao, Z.,
and Rosenfeld, M. G.
(1992)
Science
256,
370-373 |
| 6. |
Enslen, H.,
and Soderling, T. R.
(1994)
J. Biol. Chem.
269,
20872-20877 |
| 7. | Bronstein, J. M., Farber, D. B., and Wasterlain, C. G. (1993) Brain Res. Rev. 18, 135-147[CrossRef][Medline] [Order article via Infotrieve] |
| 8. |
Castellot, J. J., Jr.,
Choay, J.,
Lormeau, J. C.,
Petitou, M.,
Sache, E.,
and Karnovsky, M. J.
(1986)
J. Cell Biol.
102,
1979-1984 |
| 9. | Caleb, B. L., Hardenbrook, M., Cherington, P. V., and Castellot, J. J., Jr. (1996) J. Cell. Physiol. 167, 185-195[CrossRef][Medline] [Order article via Infotrieve] |
| 10. |
Castellot, J. J., Jr.,
Pukac, L. A.,
Caleb, B. L.,
Wright, T. C., Jr.,
and Karnovsky, M. J.
(1989)
J. Cell Biol.
109,
3147-3155 |
| 11. | Ausebel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (1996) Current Protocols in Molecular Biology , pp. 286-289, Wiley and Sons, New York |
| 12. | Cochran, D. L., Castellot, J. J., Jr., and Karnovsky, M. J. (1985) J. Cell. Physiol. 124, 29-36[CrossRef][Medline] [Order article via Infotrieve] |
| 13. | Gulves, E. A., and Dice, J. F. (1989) Biochem. J. 260, 377-387[Medline] [Order article via Infotrieve] |
| 14. | Hardie, D. G., Campbell, D. G., Caudwell, F. B., and Haystead, T. A. J. (1993) in Protein Phosphorylation. A Practical Approach (Hardie, D. G., ed) , pp. 113-118, IRL Press, Oxford |
| 15. | Mishra-Gorur, K., and Castellot, J. J. (1997) Mol. Biol. Cell 8, 401a (abstr.) |
| 16. |
Schworer, C. M.,
Rothblum, L. I.,
Thekkumkara, T. J.,
and Singer, H. A.
(1993)
J. Biol. Chem.
268,
14443-14449 |
| 17. |
Abraham, S. T.,
Benscoter, H. A.,
Schworer, C. M.,
and Singer, H. A.
(1997)
Circ. Res.
81,
575-584 |
| 18. | Pukac, L. A., Carter, J. E., Ottlinger, M. E., and Karnovsky, M. J. (1997) J. Cell. Physiol. 172, 69-78[CrossRef][Medline] [Order article via Infotrieve] |
| 19. |
Herbert, J. M.,
Clowes, M.,
Lea, H. J.,
Pascal, M.,
and Clowes, A. W.
(1996)
J. Biol. Chem.
271,
25928-25935 |
| 20. |
Ottlinger, M. E.,
Pukac, L. A.,
and Karnovsky, M. J.
(1993)
J. Biol. Chem.
268,
19173-19176 |
| 21. | Chan, Y.-L., Paz, V., and Wool, I. G. (1991) Biochem. Biophys. Res. Commun. 178, 1212-1218[CrossRef][Medline] [Order article via Infotrieve] |
| 22. | Garwood, J., and Lepesant, J.-A. (1994) Gene (Amst.) 141, 231-235[CrossRef][Medline] [Order article via Infotrieve] |
| 23. | Boileau, G., Butler, P., Hershey, J. W., and Traut, R. R. (1983) Biochemistry 22, 3162-3170[CrossRef][Medline] [Order article via Infotrieve] |
| 24. | Powers, T., Stern, S., Changchien, L. M., and Noller, H. F. (1988) J. Mol. Biol. 201, 697-716[CrossRef][Medline] [Order article via Infotrieve] |
| 25. |
Osswald, M.,
Doring, T.,
and Brimacombe, R.
(1995)
Nucleic Acids Res.
23,
4635-4641 |
| 26. | Heilik, G. M., and Noller, H. F. (1996) RNA 2, 597-602[Abstract] |
| 27. |
Pohl, T.,
and Wittman-Liebold, B.
(1988)
J. Biol. Chem.
263,
4293-4301 |
| 28. | Wower, J., Malloy, T. A., Hixson, S. S., and Zimmermann, R. A. (1990) Biochim. Biophys. Acta 1050, 38-44[Medline] [Order article via Infotrieve] |
| 29. | Issinger, O. G., Kiefer, M. C., and Traut, R. R. (1975) Eur. J. Biochem. 59, 137-143[CrossRef][Medline] [Order article via Infotrieve] |
| 30. | Faxen, M. A., Granberg, W., and Isaksson, L. A. (1994) Biochim. Biophys. Acta 1218, 27-34[Medline] [Order article via Infotrieve] |
| 31. |
Schwarzbauer, J.,
and Craven, G. R.
(1985)
Nucleic Acids Res.
13,
6767-6786 |
| 32. | Tazi, K. A., Bonnafous, M., Favre, G., Soula, G., and Le Gaillard, F. (1995) Biochem. J. 307, 557-561 |
| 33. |
Fawell, E. H.,
Boyer, I. J.,
Brostrom, M. A.,
and Brostrom, C. O.
(1989)
J. Biol. Chem.
264,
1650-1655 |
| 34. | Mishra-Gorur, K., Singer, H. A., and Castellot, J. J., Jr. (2002) Am. J. Pathol., in press |
This article has been cited by other articles:
![]() |
S. J. House, R. G. Ginnan, S. E. Armstrong, and H. A. Singer Calcium/calmodulin-dependent protein kinase II-{delta} isoform regulation of vascular smooth muscle cell proliferation Am J Physiol Cell Physiol, June 1, 2007; 292(6): C2276 - C2287. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Fasciano, R. C. Patel, I. Handy, and C. V. Patel Regulation of Vascular Smooth Muscle Proliferation by Heparin: INHIBITION OF CYCLIN-DEPENDENT KINASE 2 ACTIVITY BY p27kip1 J. Biol. Chem., April 22, 2005; 280(16): 15682 - 15689. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Dresios, A. Aschrafi, G. C. Owens, P. W. Vanderklish, G. M. Edelman, and V. P. Mauro Cold stress-induced protein Rbm3 binds 60S ribosomal subunits, alters microRNA levels, and enhances global protein synthesis PNAS, February 8, 2005; 102(6): 1865 - 1870. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |